Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 5,585 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 5,585 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.49, for a total transaction of $19,491.65. Following the transaction, the chief executive officer now directly owns 3,039,194 shares in the company, valued at $10,606,787.06. The trade was a 0.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Organogenesis Price Performance

Shares of ORGO opened at $3.57 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The firm has a 50-day simple moving average of $3.45 and a 200-day simple moving average of $3.01. The company has a market capitalization of $473.30 million, a price-to-earnings ratio of -59.50 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. During the same period last year, the firm earned $0.02 EPS. On average, equities research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Hedge Funds Weigh In On Organogenesis

Large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its stake in shares of Organogenesis by 2.4% during the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock worth $8,605,000 after acquiring an additional 72,696 shares during the period. AQR Capital Management LLC boosted its holdings in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Organogenesis by 19.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares during the period. State Street Corp raised its stake in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after buying an additional 9,090 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Organogenesis by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after buying an additional 23,675 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.